ISR · IsoRay, Inc

-

Please sign in to comment on ISR

1 Comment

Admin

4 years ago

Isoray, Inc is currently in a long term downtrend where the price is trading 18.6% below its 200 day moving average.

From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.0.

Isoray, Inc's total revenue rose by 6.9% to $2M since the same quarter in the previous year.

Its net income has increased by 99.9% to $-868 since the same quarter in the previous year.

Finally, its free cash flow grew by 8.2% to $-1M since the same quarter in the previous year.

Based on the above factors, Isoray, Inc gets an overall score of 4/5.

Sector	Healthcare
ISIN	US46489V1044
Industry	Healthcare Equipment & Supplies
Exchange	NYSE MKT
CurrencyCode	USD

Target Price	1
Dividend Yield	0.0%
Beta	1.49
PE Ratio	None
Market Cap	107M

ABOUT

IsoRay, Inc

Isoray, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

ISR · IsoRay, Inc

-

IsoRay, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest IsoRay, Inc using a moving average strategy